Table of Contents
WYE-354 6μM R02 exp90
Mechanism of Action
Inhibits mTORC1 and mTORC2, ATP-competitive inhibitor
- Class / Subclass 1: Signal Transduction / Kinase Inhibitor
- Class / Subclass 2: Proteostasis / mTOR inhibitor
Technical Notes
Compound References
- PubChem Name: CID 44219749
- Synonyms: N/A
- CAS #: 1062169-56-5
- PubChem CID: 44219749
- IUPAC: methyl 4-[6-[4-(methoxycarbonylamino)phenyl]-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate
- INCHI Name: InChI=1S/C24H29N7O5/c1-34-23(32)26-17-5-3-16(4-6-17)20-27-21(29-11-13-36-14-12-29)19-15-25-31(22(19)28-20)18-7-9-30(10-8-18)24(33)35-2/h3-6,15,18H,7-14H2,1-2H3,(H,26,32)
- INCHI Key: IMXHGCRIEAKIBU-UHFFFAOYSA-N
- Molecular Weight: 495.5
- Canonical SMILES: COC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCN(CC4)C(=O)OC)C(=N2)N5CCOCC5
- Isomeric SMILES: N/A
- Molecular Formula: C24H29N7O5
Compound Supplier
- Supplier Name: Selleck Chemicals
- Catalog #: S1266
- Lot #: N/A
Compound Characterization
- HRMS (ESI-TOF) m/z: (M+H)+ Calcd for C24H29N7O5 496.23029; found 496.23044
Dose Response Curve
- Platform ID: WYE-354
- Min: -8.8886; Max: 64.9280
| IC | Concentration (µM) |
|---|---|
| IC10 | N/A |
| IC20 | 0.3091 |
| IC30 | 0.5848 |
| IC40 | 0.9864 |
| IC50 | 1.5936 |
| IC60 | N/A |
| IC70 | N/A |
| IC80 | N/A |
| IC90 | N/A |
Screen Summary
- Round: 02
- Dose: 6µM
- Days of incubation: 8
- Doublings: 2.3
- Numbers of reads: 8071417
Screen Results
| Sensitive/Resistant hits (FDR<0.05) | CRANKS | Score Plot | Top 30 Genes | Screen Similarity | Top 30 Sensitive GO terms | Top 30 Resistant GO terms |
|---|---|---|---|---|---|---|
| 25/3 | Scores |
WYE-354 6μM R02 exp90
WYE-354 6μM R02 exp90 vs ZLN024 50μM R08 exp538
WYE-354 6μM R02 exp90 vs Wortmannin 5μM R00 exp38
BH1 1μM R04 exp169 vs WYE-354 6μM R02 exp90
Cannabidiol 20μM R08 exp466 vs WYE-354 6μM R02 exp90
BS-181 20μM R08 exp461 vs WYE-354 6μM R02 exp90
CB-839 10μM R05 exp224 vs WYE-354 6μM R02 exp90
Lapatinib 5μM R01 exp47 vs WYE-354 6μM R02 exp90
CFI-400945 25μM R08 exp469 vs WYE-354 6μM R02 exp90
BVD-523 15μM R02 exp67 vs WYE-354 6μM R02 exp90
MK2206 4μM R08 exp504 vs WYE-354 6μM R02 exp90
FK-506 30μM R07 exp359 vs WYE-354 6μM R02 exp90
Clomiphene 4.4μM R02 exp68 vs WYE-354 6μM R02 exp90
∆-9-Tetrahydrocannabinol 30μM R08 exp445 vs WYE-354 6μM R02 exp90
Bisphenol A 100μM R06 exp269 vs WYE-354 6μM R02 exp90
Chlorpromazine 10μM R07 exp344 vs WYE-354 6μM R02 exp90
Cryptotanshinone 12μM R05 exp227 vs WYE-354 6μM R02 exp90
Pterostilbene 16μM R02 exp78 vs WYE-354 6μM R02 exp90
Thioridazine 5μM R08 exp530 vs WYE-354 6μM R02 exp90
Monensin 0.3μM R08 exp507 vs WYE-354 6μM R02 exp90
EPZ-5676 30μM R05 exp233 vs WYE-354 6μM R02 exp90
Nicotine 3000μM R08 exp510 vs WYE-354 6μM R02 exp90
Q15 1 to 2μM on day4 R04 exp164 vs WYE-354 6μM R02 exp90
Q15 2.7μM R02 exp79 vs WYE-354 6μM R02 exp90
CCT251545 20μM R07 exp326 vs WYE-354 6μM R02 exp90
Prochlorperazine 5.2μM R02 exp77 vs WYE-354 6μM R02 exp90
Vemurafenib 6.6μM R02 exp89 vs WYE-354 6μM R02 exp90
